Genomize-SEQ: An NGS data analysis platform for genomic variant classification and prioritization
Kavak, E.; Aslan, T.; Karaman, R.; Aydin, C.; Ozer, T.; Sunnetci Akkoyunlu, D.; Savli, H.; Cine, N.; Seker, T.
Show abstract
Accurate interpretation of diverse genetic variants remains a pivotal challenge in the diagnosis of rare diseases. Although evidence-based guidelines established by the American College of Medical Genetics and Genomics have enhanced the precision of variant assessment, the practical implementation of this evidence-based classification can be challenging. The inherent genetic heterogeneity in rare diseases, coupled with the need to integrate information from numerous databases, contributes to this complexity. Therefore, advancements in secondary variant calling, automated variant annotation and prioritization, visualization of variant annotations with the raw data, and a streamlined reporting process are crucial for efficient and robust analysis. Here we present Genomize-SEQ, a web-based clinical genomics analysis software that has all of these capabilities, with which more than 300,000 patients have been analyzed to date. Genomize-SEQ collects data from more than 120 different databases to annotate the variants according to ACMG/AMP guidelines and prioritize the variants that could be causative for the clinical presentation of a patient. Genomize-SEQ can also perform real-time data aggregation to calculate variant frequencies in each center as well as the community. This capability helps clinicians to analyze variants more easily in regions without genome projects or in populations underrepresented in existing databases. We validated the annotation capacity of Genomize-SEQ by performing a systematic comparison of ACMG pathogenicity prediction from widely used algorithms and Genomize-SEQs algorithm, using ClinGens expert curation dataset as a truth set. In addition, we tested the prioritization efficiency of Genomize-SEQ by using real-world whole-exome sequencing data of 215 patients with pre-diagnostic and phenotypic information. Genomize-SEQ identified the causative variants with a 97% success rate, with 52% of these variants ranked in the top position and over 90% ranked within the top 20. Thus, Genomize-SEQ provides a complete solution for comprehensive variant interpretation to achieve fast and reliable diagnosis for rare diseases from next-generation sequencing data.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- MetaRNN: Differentiating Rare Pathogenic and Rare Benign Missense SNVs and InDels Using Deep Learning 96%
- varCADD: large sets of standing genetic variation enable genome-wide pathogenicity prediction 95%
- Evaluating Genome Sequencing Strategies: Trio, Singleton, and Standard Testing in Rare Disease Diagnosis 94%
Similar papers in this journal
- GeneBreaker: Variant simulation to improve the diagnosis of Mendelian rare genetic diseases 95%
- Matching whole genomes to rare genetic disorders: Identification of potential causative variants using phenotype-weighted knowledge in the CAGI SickKids5 clinical genomes challenge 94%
- Phasing of de novo mutations using a scaled-up multiple amplicon long-read sequencing approach 94%
Similar papers in this journal
- HiFi long-read genomes for difficult-to-detect clinically relevant variants 96%
- Advancing long-read nanopore genome assembly and accurate variant calling for rare disease detection 96%
- Advanced variant classification framework reduces the false positive rate of predicted loss of function (pLoF) variants in population sequencing data 94%
Similar papers in this journal
- The Importance of Automation in Genetic Diagnosis: Lessons from Analyzing an Inherited Retinal Degeneration Cohort with the Mendelian Analysis Toolkit (MATK) 96%
- Informing Variant Assessment using Structured Evidence from Prior Classifications (PS1, PM5, and PVS1 Sequence Variant Interpretation Criteria) 95%
- Genome Alert!: a standardized procedure for genomic variant reinterpretation and automated genotype-phenotype reassessment in clinical routine 95%
Similar papers in this journal
- The MorbidGenes panel: a monthly updated list of diagnostically relevant rare disease genes derived from diverse sources 94%
- Targeting de novo loss of function variants in constrained disease genes improves diagnostic rates in the 100,000 Genomes Project 93%
- High-throughput PRPF31 variant characterisation pipeline consistent with ACMG/AMP clinical variant interpretation guidelines 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.